Metacrine MTCR shares are trading higher on Monday after multiple firms initiated coverage on the stock with a bullish rating.
Metacrine is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases.
Metacrine shares traded up 6.83% to $10.86 on Monday at the time of publication. The stock has a 52-week high of $16.19 and a 52-week low of $9.06.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in